How PT-141 worksBremelanotide, the melanocortin pathway, and the research

From $54.50 first monthStart a visit

PT-141 · the mechanism

Desire has a pathway. PT-141 speaks to it.

Bremelanotide is an agonist at the MC3R and MC4R melanocortin receptors, in the brain.

The older category treats blood flow and hopes the wanting takes care of itself. PT-141 is aimed at the wanting. That is a different target, and for a lot of people it is the one that was missing.

A central receptor target, not a vascular one
Studied in people by the group that developed it
Taken when you want it, up to eight times a month
Available as a troche or a nasal spray

Start a visit Read the research

BremelanotideThe compound in every format

MC3R and MC4RThe receptors it activates

Central, not vascularWhere it acts

As neededNot a daily medicine

Two different addresses

One drug class moves blood. This one moves interest.

Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone. It activates melanocortin receptors that sit in the central nervous system, on pathways involved in sexual behaviour. PDE5 medicines work much further downstream, on smooth muscle and blood flow in peripheral tissue.

01
The signal, not the plumbing
If the interest is not there, opening a blood vessel does not produce it. Melanocortin signalling is upstream of that.
02
An agonist, not a blocker
Bremelanotide binds MC3R and MC4R and switches them on rather than stopping an enzyme from switching something off.
03
Occasional by design
It is taken before you want it, up to eight times a month, not swallowed every morning whether you need it or not.

Start a visit

A single signalling molecule crossing the gap between two receptor-covered cell surfaces.

Four questions, one offer

The research, read the way it was actually run.

Bremelanotide went through phase 3 as an injection and through early human work as a nasal spray. Each answer below says which product was tested, and the offer stays beside it.

Dissolves in the mouth

What has actually been measured in people?

Bremelanotide went through a full phase 3 programme as a subcutaneous injection. Two randomized trials, 1,267 premenopausal women with hypoactive sexual desire disorder, 24 weeks of treatment. Desire scores rose against placebo and distress about low desire fell.

1,267women randomized across the two phase 3 trials

24 weeksof randomized treatment in both studies

0.35integrated rise in the desire-domain score against placebo, P<.001

−0.33integrated fall in low-desire distress against placebo, P<.001

Kingsberg SA et al. Obstet Gynecol. 2019;134(5):899-908. Those figures come from the 1.75 mg subcutaneous autoinjector, which is a different product from the Rebody troche and nasal spray.

Absorbed through the nose

Does the research cover the route I would be taking?

Read it route by route rather than treating one result as covering everything. The receptor target does not change, but how much reaches you and how fast does.

The injectionRECONNECT randomized 1,267 premenopausal women with hypoactive sexual desire disorder to 1.75 mg subcutaneous bremelanotide as needed or placebo, over 24 weeks. Kingsberg SA et al. Obstet Gynecol. 2019;134(5):899-908. That is the FDA-approved autoinjector, a different product from the Rebody troche and nasal spray.
The nasal routeEighteen premenopausal women with sexual arousal disorder took a single 20 mg intranasal dose against placebo, and more reported moderate or high desire on bremelanotide (P = 0.0114). A second study found a statistically significant erectile response in men above 7 mg. Diamond LE et al. J Sex Med. 2006 and Int J Impot Res. 2004, both research formulations at research doses.
The trocheBremelanotide's action at melanocortin receptors is the same whichever way it reaches you, but no published human outcome or pharmacokinetic trial has tested a PT-141 troche. We do not claim one. Rebody research note, 2026.

Dissolves in the mouth

How fast does it work?

In the 2004 intranasal study the first erectile response began at roughly 30 minutes, median time to peak concentration was 0.50 hours, and half-life ran 1.85 to 2.09 hours. Rebody's nasal spray directions place the dose 30 to 60 minutes before activity.

It is not a daily medicine. You take it before you want it, up to eight times a month, and there is nothing to take on the nights you do not.

Hands fastening a cuff beside a small mirror in bright morning light.

Absorbed through the nose

Which way in should I pick?

The troche is the cheaper way onto the pathway and it comes in two strengths, so a provider has a dial to turn. The nasal spray is the route the early human studies used.

TrocheSublingual or buccal mini troche

Nasal sprayMetered nasal spray

TimingBefore you want it, no clock to watch

Timing30 to 60 minutes before

First month$54.50, then $109

First month$99.50, then $199

See every price

Mechanism questions

The parts people ask about twice.

Receptors, timing, route differences, and how this compares with the approved injection.

What is a melanocortin receptor agonist?

Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone. It binds and activates the melanocortin receptors MC3R and MC4R. Melanocortins take part in several physiological responses, sexual behaviour among them.

How is that different from a PDE5 medicine?

PDE5 medicines act on smooth muscle and blood flow in peripheral tissue. They assume the desire is already there. PT-141 acts on central melanocortin receptors, which sit on the circuitry involved in desire itself.

How fast does it work?

In the 2004 intranasal study, the first erectile response began at roughly 30 minutes, median time to peak concentration was 0.50 hours, and half-life ran 1.85 to 2.09 hours. Rebody's nasal spray directions place the dose 30 to 60 minutes before activity.

Does the route change what the compound does?

The receptor target is the same. What a route changes is how much reaches the bloodstream and how quickly. That is why the published research is worth reading route by route rather than treating one result as covering everything.

Is the Rebody product the same as Vyleesi?

No. Vyleesi is the FDA-approved 1.75 mg bremelanotide autoinjector for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Rebody's troche and nasal spray are compounded prescription medications and do not carry that approval or that indication.

Does PT-141 work for men?

Published intranasal research included healthy men and men with mild-to-moderate erectile dysfunction. Rebody prescribes PT-141 to men and women after a licensed provider reviews the visit.

Important safety information

What a provider needs to know before prescribing.

Bremelanotide's approved label is contraindicated in uncontrolled high blood pressure and in known cardiovascular disease. Tell your provider your blood pressure, your heart history, every medicine and supplement you take, whether you take naltrexone, and whether you are pregnant or breastfeeding.

Nausea, flushing, and headache were the reactions most often reported in bremelanotide trials. The approved label also covers a temporary rise in blood pressure, a fall in heart rate, and darkening of skin in patches. Get urgent care for hives, swelling, trouble breathing, chest tightness, or fainting.

The FDA-approved bremelanotide product is Vyleesi, a 1.75 mg subcutaneous autoinjector for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Rebody's troche and nasal spray are compounded prescription medications. They are a different product and they do not carry that approval or that indication.

Compounded medications are not FDA-approved or evaluated by the FDA for safety, efficacy, or quality. Prescription treatment requires a provider decision and is not available in every state.

A woman standing at a rain-flecked window in low evening light.

PT-141 care

Treat the wanting, not the plumbing.

Two needle-free routes from $54.50 for your first month, with the visit, the provider review, and delivery included.

Start with the troche Start with the nasal spray